Japan is preparing to launch clinical trials for a groundbreaking medical innovation: universal artificial blood that can be safely used by anyone, regardless of blood type.
Developed by Japanese researchers, this artificial blood does not require compatibility matching and has a significantly longer shelf life than regular human blood — potentially up to one year compared to the usual 28 to 42 days.
The synthetic blood is designed to carry oxygen and mimic key functions of red blood cells, making it especially valuable in emergency situations, remote areas, and during disasters where matching and supply are critical challenges.
Health authorities see this development as a major advancement in transfusion medicine, with the potential to ease global blood shortages and improve trauma care in hospitals and battlefields alike.
If trials succeed, Japan’s universal artificial blood could mark a new chapter in lifesaving technology — where timely access, not blood type, becomes the deciding factor in survival.
